vs
Side-by-side financial comparison of KKR Real Estate Finance Trust Inc. (KREF) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
KKR Real Estate Finance Trust Inc. is the larger business by last-quarter revenue ($25.8M vs $20.6M, roughly 1.3× Entrada Therapeutics, Inc.). Entrada Therapeutics, Inc. runs the higher net margin — -84.4% vs -101.7%, a 17.4% gap on every dollar of revenue. On growth, KKR Real Estate Finance Trust Inc. posted the faster year-over-year revenue change (-26.6% vs -65.2%). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -18.8%).
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
KREF vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $20.6M |
| Net Profit | $-26.2M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | -105.1% | -106.0% |
| Net Margin | -101.7% | -84.4% |
| Revenue YoY | -26.6% | -65.2% |
| Net Profit YoY | -229.6% | -173.8% |
| EPS (diluted) | $-0.49 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | — | ||
| Q3 25 | $25.3M | — | ||
| Q2 25 | $30.2M | — | ||
| Q1 25 | $31.3M | $20.6M | ||
| Q4 24 | $35.1M | $37.4M | ||
| Q3 24 | $37.0M | $19.6M | ||
| Q2 24 | $40.4M | $94.7M | ||
| Q1 24 | $39.1M | $59.1M |
| Q4 25 | $-26.2M | — | ||
| Q3 25 | $13.8M | — | ||
| Q2 25 | $-29.7M | — | ||
| Q1 25 | $-4.9M | $-17.3M | ||
| Q4 24 | $20.3M | $1.1M | ||
| Q3 24 | $-7.4M | $-14.0M | ||
| Q2 24 | $25.8M | $55.0M | ||
| Q1 24 | $-3.1M | $23.5M |
| Q4 25 | -105.1% | — | ||
| Q3 25 | 50.4% | — | ||
| Q2 25 | -101.3% | — | ||
| Q1 25 | -18.3% | -106.0% | ||
| Q4 24 | 55.8% | -15.7% | ||
| Q3 24 | -19.6% | -110.7% | ||
| Q2 24 | 63.3% | 56.4% | ||
| Q1 24 | -8.7% | 35.7% |
| Q4 25 | -101.7% | — | ||
| Q3 25 | 54.4% | — | ||
| Q2 25 | -98.5% | — | ||
| Q1 25 | -15.5% | -84.4% | ||
| Q4 24 | 57.7% | 3.0% | ||
| Q3 24 | -20.0% | -71.7% | ||
| Q2 24 | 63.9% | 58.1% | ||
| Q1 24 | -7.9% | 39.7% |
| Q4 25 | $-0.49 | — | ||
| Q3 25 | $0.12 | — | ||
| Q2 25 | $-0.53 | — | ||
| Q1 25 | $-0.15 | $-0.42 | ||
| Q4 24 | $0.22 | $-0.20 | ||
| Q3 24 | $-0.19 | $-0.35 | ||
| Q2 24 | $0.29 | $1.55 | ||
| Q1 24 | $-0.13 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.6M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $417.3M |
| Total Assets | $6.5B | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.6M | — | ||
| Q3 25 | $204.1M | — | ||
| Q2 25 | $107.7M | — | ||
| Q1 25 | $106.4M | $67.8M | ||
| Q4 24 | $104.9M | $101.2M | ||
| Q3 24 | $108.8M | $78.0M | ||
| Q2 24 | $107.2M | $185.3M | ||
| Q1 24 | $106.5M | $68.4M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | $417.3M | ||
| Q4 24 | $1.3B | $428.7M | ||
| Q3 24 | $1.4B | $422.4M | ||
| Q2 24 | $1.4B | $429.9M | ||
| Q1 24 | $1.4B | $269.4M |
| Q4 25 | $6.5B | — | ||
| Q3 25 | $6.5B | — | ||
| Q2 25 | $6.8B | — | ||
| Q1 25 | $6.6B | $486.5M | ||
| Q4 24 | $6.4B | $526.3M | ||
| Q3 24 | $6.8B | $554.6M | ||
| Q2 24 | $7.1B | $582.0M | ||
| Q1 24 | $7.3B | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $72.3M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $72.3M | — | ||
| Q3 25 | $18.5M | — | ||
| Q2 25 | $21.1M | — | ||
| Q1 25 | $15.9M | $-38.5M | ||
| Q4 24 | $132.6M | $-31.6M | ||
| Q3 24 | $49.1M | $-24.3M | ||
| Q2 24 | $30.6M | $39.8M | ||
| Q1 24 | $34.5M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
